View as an RSS Feed
With Ebola Looming, When Will The Defense Department Get Around To Generex?
- The infectious agent Ebola is already beginning to kill hundreds and hundreds. The Defense Department needs to fund start-ups who have relevant technologies.
- Generex has "off-the-shelf" antigen technology it can bring to bear.
- Generex already has in the pipeline products for Avian Flu, Swine Flu, and HIV.
From 1930 To 1995, The P/E Peak Was 24 In January 1966
- P/E of 24 was high for 1930-1995.
- Interest rates may increase; avoid bonds.
- Look for stocks with increasing dividends.
- Generex: A Stock Suitable Only For Its Officers And Directors Or Carl Icahn
- Acquisition Target: CounterPath Corp.
- Ben Bernanke Owns This Bubble, Baby
- BlackBerry 10 And The Battle Of The Network Mobile Operating Systems
- Generex: Research For Sale On The Cheap
- No Hedge Funds Inside Banks
- AT&T And Verizon Are Progressing In Transformation To Data Transmission Utilities
- Remember When Cisco Had A Market Cap Of $500 Billion? What About Apple?
- The Impact of Technology: Unemployment May Be More Stubborn This Time
- Facebook Is to LinkedIn as Skype Is to Counterpath Corp.
- Facebook Goes Asocial
- Research In Motion Needs to Circle Back to the Enterprise
- Why Major Telecoms Are in Trouble
- Microsoft and Skype: The Take Away
- Microsoft: Overview of a Possible Also-Ran
- Generex: Do Development Drug Companies Have No Value?
- News Next Week for Generex May Reduce Need for Reverse Split
- Generex: Reverse Split Not Approved
- Generex Brouhaha: Big Pharma Is Actually Not So Smart
- Big Pharma: Where's the Risk Management?
- This Is Where Sisyphus Starts Huffing and Puffing